AB MAGNITUDE VENTURES GROUP
AB MAGNITUDE VENTURES GROUP is a Seed, Series A, Series C+, early-stage-venture-capital and early-stage-vc fund in the US investing in healthcare-tech, biotechnology, therapeutics, computational-drug-discovery, consumer-products, consumer-services and information-technology.
- Stages
- Seed, Series A, Series C+, early-stage-venture-capital, early-stage-vc
- Sectors
- healthcare-tech, biotechnology, therapeutics, computational-drug-discovery, consumer-products, consumer-services, information-technology
- Invests in
- US-wide
- Actively investing
- Yes
- Founded
- 2021
- Website
- abmagnitudefund.com
Check size not disclosed
Thesis
AB Magnitude Ventures Group, founded in 2021 and based in Cambridge, MA, is a venture capital firm with a strong scientific focus, primarily investing in the healthcare sector, with a specialization in biotechnology and therapeutics, including computational drug discovery. Their investment thesis is centered on empowering scientist-entrepreneurs who are translating complex research into practical applications. They offer not only capital but also deep scientific expertise and mentorship, embodying a 'scientists helping scientists' philosophy. The firm targets companies in healthcare, consumer products, consumer services, and information technology. While specific fund sizes and AUM are not publicly disclosed, they invest across various stages, including early-stage venture capital, with a primary geographic focus on the United States. Their unique approach combines capital with scientific collaboration, aiming to foster innovation in areas like computational drug discovery.
Common questions
Does AB MAGNITUDE VENTURES GROUP invest at the Seed stage?
Yes. AB MAGNITUDE VENTURES GROUP lists Seed, Series A, Series C+, early-stage-venture-capital and early-stage-vc among the stages it invests in.
Where does AB MAGNITUDE VENTURES GROUP invest?
AB MAGNITUDE VENTURES GROUP invests in the US.